UNMC
Omaha, Neb – Nebraska Medicine CEO James Linder, MD, has been named the chair of the Nebraska Medicine Board of Directors, replacing Jeffrey P. Gold, MD, who was recently chosen to be president of the University of Nebraska system. The board unanimously voted to make Dr. Linder its next chair. He begins this new role immediately in addition to continuing his duties as CEO. Dr. Linder’s new title is Nebraska Medicine CEO and chair of the board.
“Dr. Gold provided outstanding leadership since Nebraska Medicine was organized 10 years ago. He can now bring transformative leadership to the University of Nebraska system,” Dr. Linder says. “I am immensely pleased to work with the Nebraska Medicine Board members. The Board and its subcommittees include some of the best business minds and community leaders. Their contributions are unmatched as we meet our missions as an academic medical center and provider of the best health care to Nebraska.”
Nebraska Medicine is an independent, non-profit organization and its board is solely responsible for the governance of the health system. It’s made up of leaders in business, health care and academics – including leaders with deep ties to UNMC and Clarkson College. Dele Davies, MD, who was named interim UNMC chancellor last week, also becomes a voting member of the board.
“It’s difficult to think of someone better suited to serve as board chair than Dr. Linder,” said Mogens Bay, chairman of Valmont Industries and vice-chair of the Nebraska Medicine Board of Directors. “He brings experience in leading clinical care, research and education, as well as years of work in the business and philanthropy communities. The board also recognizes Dr. Linder’s skill as a mentor and someone who will develop the leaders of the future.”
Dr. Linder has been Nebraska Medicine CEO since 2018 and part of the UNMC faculty for more than 40 years. His past leadership roles include interim roles as president of the University of Nebraska system and Dean of the UNMC College of Medicine. His research efforts led to new screening technologies that reduced the incidence of cervical cancer, as well as the development of a hematology instrument which enabled the rapid diagnosis of blood disorders.
Dr. Linder and his wife, Karen, co-lead Linseed Capital and co-chair the University of Nebraska Foundation’s “Only in Nebraska” campaign, which is in the process of raising $1 billion in charitable support for Nebraska Medicine and UNMC.